Использование ингибиторов ароматазы для быстрого купирования симптомов гиперстимуляции яичников, возникших при проведении программы экстракорпорального оплодотворения

1. Регистр ВРТ РАРЧ. 2017: Отчет регистра за 2017 г. и ВРТ в России 2017 г. (Доклад президента РАРЧ на XXIX международной конференции РАРЧ «Репродуктивные технологии сегодня и завтра», Ростов-на-Дону).
2. Mathur R.S., Tan B.K. British Fertility Society Policy and Practice Committee: prevention of ovarian hyperstimulation syndrome. Hum. Fertil. (Camb). 2014; 17(4): 257-68. https://dx.doi.org/10.3109/14647273.2014.961745.
3. Fouda U.M., Sayed A.M., Elshaer H.S., Hammad B.E., Shaban M.M., Elsetohy K.A. et al. GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial. J. Ovarian Res. 2016; 9(1): 29. https://dx.doi.org/10.1186/s13048-016-0237-8.
4. Tang H., Mourad S., Zhai S.D., Hart R.J. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst. Rev. 2016; (11): CD008605. https://dx.doi.org/10.1002/14651858.CD008605.pub3.
5. Lainas T.G., Sfontouris I.A., Zorzovilis I.Z., Petsas G.K., Lainas G.T., Kolibianakis E.M. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod. Biomed. Online. 2007; 15(4): 408-12. https://dx.doi.org/10.1016/s1472-6483(10)60366-5.
6. Latouche J., Crumeyrolle-Arias M., Jordan D., Kopp N., Augendre-Ferrante B., Cedard L. et al. GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology. 1989; 125(3): 1739-41. https://dx.doi.org/ 10.1210/endo-125-3-1739.
7. Minaretzis D., Jakubowski M., Mortola J.F., Pavlou S.N. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J. Clin. Endocrinol. Metab. 1995; 80(2): 430-4. https://dx.doi.org/10.1210/jcem.80.2.7852501.
8. Asimakopoulos B., Nikolettos N., Nehls B., Diedrich K., Al-Hasani S., Metzen E. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil. Steril. 2006; 86(3): 636-41. https://dx.doi.org/10.1016/j.fertnstert.2006.01.046.
9. Taylor P.D., Hillier S.G., Fraser H.M. Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. J. Endocrinol. 2004; 183(1): 1-17. https://dx.doi.org/10.1677/joe.1.05685.
10. Fridén B.E., Nilsson L. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization. Acta Obstet. Gynecol. Scand. 2005; 84(8): 812-6. https://dx.doi.org/10.1111/j.0001-6349.2005.00730.x.
11. Del Canto F., Sierralta W., Kohen P., Muñoz A., Strauss J.F., Devoto L. Features of natural and gonadotropin-releasing hormone antagonist-induced corpus luteum regression and effects of in vivo human chorionic gonadotropin. J. Clin. Endocrinol. Metab. 2007; 92(11): 4436-43. https://dx.doi.org/10.1210/jc.2007-0125.
12. Sahin N., Apaydin N., Toz E., Sivrikoz O.N., Genc M., Turan G.A. et al. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome. Arch. Gynecol. Obstet. 2016; 293(5): 1101-6. https://dx.doi.org/10.1007/s00404-015-3987-4.
13. Haas J., Bassil R., Gonen N., Meriano J., Jurisicova A., Casper R.F. The VEGF and PEDF levels in the follicular fluid of patients co- treated with LETROZOLE and gonadotropins during the stimulation cycle. Reprod. Biol. Endocrinol. 2018; 16(1): 54. https://dx.doi.org/10.1186/s12958-018-0367-5.

Поступила 03.09.2020

Принята в печать 21.10.2020